Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications

被引:10
|
作者
Friberger, Ida [1 ]
Jussing, Emma [2 ,3 ]
Han, Jinming [1 ,4 ]
Goos, Jeroen A. C. M. [1 ,2 ,3 ]
Siikanen, Jonathan [2 ,5 ]
Kaipe, Helen [6 ,7 ]
Lambert, Melanie [8 ]
Harris, Robert A. [1 ,4 ]
Samen, Erik [2 ,3 ]
Carlsten, Mattias [8 ,9 ]
Holmin, Staffan [1 ,10 ]
Tran, Thuy A. [1 ,2 ,3 ]
机构
[1] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
[2] Karolinska Inst, Dept Oncol & Pathol, Stockholm, Sweden
[3] Karolinska Univ Hosp, Dept Radiopharm, Stockholm, Sweden
[4] Karolinska Univ Hosp, Ctr Mol Med, Stockholm, Sweden
[5] Karolinska Univ Hosp, Dept Med Radiat Phys & Nucl Med, Stockholm, Sweden
[6] Karolinska Inst, Dept Lab Med, Stockholm, Sweden
[7] Karolinska Univ Hosp, Dept Clin Immunol & Transfus Med, Stockholm, Sweden
[8] Karolinska Inst, Dept Med Huddinge, Stockholm, Sweden
[9] Karolinska Univ Hosp, Ctr Cell Therapy & Allogene Stem Cell Transplanta, Stockholm, Sweden
[10] Karolinska Univ Hosp, Dept Neuroradiol, Stockholm, Sweden
基金
瑞典研究理事会;
关键词
Cell labelling; Cell tracking; Zr-89; Oxine; Deferoxamine; PET; Imaging; DONOR LYMPHOCYTE INFUSION; DECIDUAL STROMAL CELLS; TRACKING; LEUKOCYTES; PET; CYTOTOXICITY; LEUKEMIA; RELAPSE;
D O I
10.1007/s11307-021-01622-z
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background There is a need to better characterise cell-based therapies in preclinical models to help facilitate their translation to humans. Long-term high-resolution tracking of the cells in vivo is often impossible due to unreliable methods. Radiolabelling of cells has the advantage of being able to reveal cellular kinetics in vivo over time. This study aimed to optimise the synthesis of the radiotracers [Zr-89]Zr-oxine (8-hydroxyquinoline) and [Zr-89]Zr-DFO-NCS (p-SCN-Bn-Deferoxamine) and to perform a direct comparison of the cell labelling efficiency using these radiotracers. Procedures Several parameters, such as buffers, pH, labelling time and temperature, were investigated to optimise the synthesis of [Zr-89]Zr-oxine and [Zr-89]Zr-DFO-NCS in order to reach a radiochemical conversion (RCC) of >95 % without purification. Radio-instant thin-layer chromatography (iTLC) and radio high-performance liquid chromatography (radio-HPLC) were used to determine the RCC. Cells were labelled with [Zr-89]Zr-oxine or [Zr-89]Zr-DFO-NCS. The cellular retention of Zr-89 and the labelling impact was determined by analysing the cellular functions, such as viability, proliferation, phagocytotic ability and phenotypic immunostaining. Results The optimised synthesis of [Zr-89]Zr-oxine and [Zr-89]Zr-DFO-NCS resulted in straightforward protocols not requiring additional purification. [Zr-89]Zr-oxine and [Zr-89]Zr-DFO-NCS were synthesised with an average RCC of 98.4 % (n = 16) and 98.0 % (n = 13), respectively. Cell labelling efficiencies were 63.9 % (n = 35) and 70.2 % (n = 30), respectively. Zr-89 labelling neither significantly affected the cell viability (cell viability loss was in the range of 1-8 % compared to its corresponding non-labelled cells, P value > 0.05) nor the cells' proliferation rate. The phenotype of human decidual stromal cells (hDSC) and phagocytic function of rat bone-marrow-derived macrophages (rMac) was somewhat affected by radiolabelling. Conclusions Our study demonstrates that [Zr-89]Zr-oxine and [Zr-89]Zr-DFO-NCS are equally effective in cell labelling. However, [Zr-89]Zr-oxine was superior to [Zr-89]Zr-DFO-NCS with regard to long-term stability, cellular retention, minimal variation between cell types and cell labelling efficiency.
引用
收藏
页码:952 / 962
页数:11
相关论文
共 50 条
  • [21] Direct Cell Labelling with 89Zr(oxine)4 allows In Vivo PET Imaging of Gamma-delta T-cells in a Breast Cancer Model
    Man, Francis
    Lim, Lindsay
    Shmeeda, Hilary
    Gabizon, Alberto
    Blower, Philip
    Fruhwirth, Gilbert
    de Rosales, Rafael T. M.
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [22] Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89Zr-immunoPET
    René Raavé
    Gerwin Sandker
    Pierre Adumeau
    Christian Borch Jacobsen
    Floriane Mangin
    Michel Meyer
    Mathieu Moreau
    Claire Bernhard
    Laurène Da Costa
    Adrien Dubois
    Victor Goncalves
    Magnus Gustafsson
    Mark Rijpkema
    Otto Boerman
    Jean-Claude Chambron
    Sandra Heskamp
    Franck Denat
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1966 - 1977
  • [23] Novel 89Zr cell labeling approach for PET-based cell trafficking studies
    Bansal, Aditya
    Pandey, Mukesh K.
    Demirhan, Yunus E.
    Nesbitt, Jonathan J.
    Crespo-Diaz, Ruben J.
    Terzic, Andre
    Behfar, Atta
    DeGrado, Timothy R.
    EJNMMI RESEARCH, 2015, 5
  • [24] Novel 89Zr cell labeling approach for PET-based cell trafficking studies
    Aditya Bansal
    Mukesh K Pandey
    Yunus E Demirhan
    Jonathan J Nesbitt
    Ruben J Crespo-Diaz
    Andre Terzic
    Atta Behfar
    Timothy R DeGrado
    EJNMMI Research, 5
  • [25] Comparison of [89Zr]Zirconium-DFO-girentuximab (89Zr-TLX250) PET/CT and PET/MRI hybrid systems in patients with suspicion of Clear Cell Renal Cell Carcinoma (ccRCC): Initial results
    Liu, Chen
    Xie, Qing
    Zhang, Yan
    Ma, Yunxia
    Liu, Shiwei
    Cerqueira, Brenda
    Brown, Tracey
    Tang, Weikun
    Du, Peng
    Yang, Zhi
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [26] Radiolabelling of human mesenchymal and hematopoietic stem cells with [89Zr]Zr-Df-Bz-NCS for possible future stem cell therapy tracking with PET
    Kahts, Maryke
    Mellet, Juanita
    Durandt, Chrisna
    Moodley, Kinosha
    Summers, Beverley
    Ebenhan, Thomas
    Zeevaart, Jan Rijn
    Aras, Omer
    Pepper, Michael
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [27] Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F] FDG-PET in patients with newly diagnosed metastatic renal cell carcinoma
    Verhoeff, S.
    van Es, S. C.
    Boon, E.
    van Helden, E.
    Angus, L.
    Elias, S. G.
    Oosting, S. F.
    Aarntzen, E. H.
    Brouwers, A. H.
    Kwee, T. C.
    Heskamp, S.
    Hoekstra, O. S.
    Verheul, H.
    Zwezerijnen, G. J. C.
    van Oordt, C. Menke-van der Houven
    van der Veldt, A. A. M.
    de Vries, E. G. E.
    Boerman, O. C.
    van der Graaf, W. T. A.
    Oyen, W. J. G.
    van Herpen, C. M. L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S67 - S67
  • [28] [89Zr]Zr-girentuximab PET-CT imaging to diagnose, characterize, and differentiate clear-cell renal cell carcinoma
    Chehade, Chadi Hage
    Gebrael, Georges
    Agarwal, Neeraj
    MED, 2024, 5 (11): : 1345 - 1347
  • [29] Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma
    Verhoeff, Sarah R.
    van Es, Suzanne C.
    Boon, Eline
    van Helden, Erik
    Angus, Lindsay
    Elias, Sjoerd G.
    Oosting, Sjoukje F.
    Aarntzen, Erik H.
    Brouwers, Adrienne H.
    Kwee, Thomas C.
    Heskamp, Sandra
    Hoekstra, Otto S.
    Verheul, Henk
    van der Veldt, Astrid A. M.
    de Vries, Elisabeth G. E.
    Boerman, Otto C.
    van der Graaf, Winette T. A.
    Oyen, Wim J. G.
    van Herpen, Carla M. L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (09) : 1931 - 1939
  • [30] Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma
    Sarah R. Verhoeff
    Suzanne C. van Es
    Eline Boon
    Erik van Helden
    Lindsay Angus
    Sjoerd G. Elias
    Sjoukje F. Oosting
    Erik H. Aarntzen
    Adrienne H. Brouwers
    Thomas C. Kwee
    Sandra Heskamp
    Otto S. Hoekstra
    Henk Verheul
    Astrid A. M. van der Veldt
    Elisabeth G. E. de Vries
    Otto C. Boerman
    Winette T. A. van der Graaf
    Wim J. G. Oyen
    Carla M. L. van Herpen
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1931 - 1939